熱門資訊> 正文
Teva提交ecopipam治疗儿童抽动秽语症的NDA
2026-06-19 05:20
- 梯瓦製藥(TEVA) 0
- 高盛(GS) 0
- 美國銀行(BAC) 0
- Teva Pharmaceutical Industries (TEVA) has submitted an NDA to the US FDA seeking approval of ecopipam for pediatric Tourette syndrome.
- The application is supported by phase 3 data that found ecopipam significantly delayed time to relapse compared to placebo during an open-label treatment period. For up to 24 weeks, Ecopipam led to and sustained a meaningful reduction in the severity of tics.
- Ecopipam is considered a first-in-class drug that works to inhibit dopamine signaling at the D1 receptor.
More on Teva Pharmaceutical
- Teva Pharmaceutical Industries Limited (TEVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
- Teva's Growth Story Is No Longer Just Generic, It's Getting Branded
- Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
- Alvotech gains on FDA acceptance of Entyvio biosimilar BLA
- Alvotech seeks U.S. nod for biosimilars to J&J’s Simponi and Regeneron’s Eylea again
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
